Agnogenic myeloid metaplasia

Cancer Investigation

Volumn 15, Issue 2, 1997, Pages 177-179

  Tefferi, Ayalew ^a   Silverstein, Murray N ^a  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYUREA;

ARTICLE; HUMAN; MYELOID METAPLASIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS;

EID: 0031003972     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909709115771     Document Type: Article

References (32)

1. Jacobson RJ, Salo A, Fialkow PJ: Agnogenic myeloid metaplasia: A clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood 51:189-194, 1978.
2. Buschle M, Janssen JW, Drexler H, et al: Evidence for pluripotent stem cell origin of idiopathic myelofibrosis: Clonal analysis of a case characterized by a N-ras gene mutation. Leukemia 2:658-660, 1988.
3. Greenberg BR, Woo L, Veomett IC, et al: Cytogetietics of bone marrow fibroblastic cells in idiopathic chronic myelofibrosis. Br J Haematol 66:487-490, 1987.
4. Wang JC, Lang HD, Lichter S, et al: Cytogenetic studies of bone marrow fibroblasts cultured from patients with myelofibrosis and myeloid metaplasia. Br J Haematol 80:184-188, 1992.
5. Terui T, Niitsu Y, MaharaK, et al: The production of transforming growth factor-beta in acute megakaryoblastic leukemia and its possible implications in myelofibrosis. Blood 75:1540-1548, 1990.
6. Martyre MC, Magdelenat H, Bryckaert MC, et al: Increased intraplatelet levels of platelet-derived growth factor and transforming growth factor-beta in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 77:80-86, 1991.
7. Ignotz RA, Massague J: Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem 261:4337-4345, 1986.
8. Kimura A, Katoh O, Hyodo H, et al: Transforming growth factor-beta regulates growth as well as collagen and fibronectin synthesis of human marrow fibroblasts. Br J Haematol 72:486-491, 1989.
9. Reilly JT, Bar neu D, Dolan G, et al: Characterization of an acute micromegakaryocytic leukaemia: Evidence for the pathogenesis of myelofibrosis. Br J Haematol 83:58-62, 1993.
10. Martyre MC, Romquin N, Le Bousse-Kerdiles MC, et al: Transforming growth factor-β and megakaryocytes in the pathogenesis of idiopathic myelofibrosis. Br J Haematol 88:9-16, 1994.
11. Silverstein MN: Agnogenic Myeloid Metaplasia. Acton, MA, Publishing Sciences Group, 1975.
12. Visani G, Finelli C, Castelli U, et al: Myelofibrosis with myeloid metaplasia: Clinical and haematological parameters predicting survival in a series of 133 patients. Br J Haematol 75:4-9, 1990.
13. Wanless IR, Peterson P, Das A, et at: Hepatic vascular disease and portal hypertension in polycythemia vera and agnogenic myeloid metaplasia: A clinicopathological study of 145 patients examined at autopsy. Hepatology 12:1166-1174, 1990.
14. Tefferi A, Barrett SM, Silverstein MN, et al: Outcome of portal-systemic shunt surgery for portal hypertension associated with intrahepatic obstruction in patients with agnogenic myeloid metaplasia. Am J Hematol 46:325-328, 1994.
15. Silverstein MN, ReMine WH: Splenectomy in myeloid metaplasia. Blood 53:515-518, 1979.
16. Demory JL, Dupriez B, Fenaux P, et al: Cytogenetic studies and their prognostic significance in agnogenic myeloid metaplasia: A report on 47 cases. Blood 72:855-859, 1988.
17. Lambertenghi-Deliliers G, Orazi A, Luksch R, et al: Myelodysplastic syndrome with increased marrow fibrosis: A distinct clinicopathological entity. Br J Haematol 78:161-166, 1991.
18. Tefferi A, Hoagland HC, Therneau TM, et al: Chronic myelomonocytic leukemia: Natural history and prognostic determinants. Mayo Clin Proc 64:1246-1254, 1989.
19. Dupriez B, Morel P, Demory JL, et al: Prognostic factors in agnogenic myeloid metaplasia (AMM). A report on 195 cases with a new simple scoring system. Blood 84 (Suppl 1);517a, 1994.
20. Tefferi A, Silverstein MN: Recombinant human erythropoietin therapy in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 86:893, 1994.
21. Barosi G, Liberate LN, Guarnone R: Serum erythropoietin in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 83:365-369, 1993.
22. Barosi G, Liberato LN, Costa A, et al: Induction and maintenance alpha-interferon therapy in myelofibrosis with myeloid metaplasia. Eur J Haematol Suppl 52:12-14, 1990.
23. Barosi G, Ambrosetti A, Buratti A, et al: Splenectomy for patients with myelofibrosis with myeloid metaplasia: Pretreatment variables and outcome prediction. Leukemia 7:200-206, 1993.
24. Silverstein MN: Control of hypersplenism and painful splenomegaly in myeloid metaplasia by irradiation, Int J Radiat Oncol Biol Phys 2:1221-1222, 1977 (editorial).
25. Greenbcrger JS, Chaffey JT, Rosenthal DS, et al: Irradiation for control of hypersplenism and painful splenomegaly in myeloid metaplasia, Int J Radiat Oncol Biol Phys 2:1083-1090, 1977.
26. Price F, Bell H: Spinal cord compression due to extramedullary hematopoiesis. Successful treatment in a patient with long-standing myelofibrosis. JAMA 253:2876-2877, 1985.
27. Bartlett RP, Greipp PR, Tefferi A, et al: Extramedullary hematopoiesis manifesting as a symptomatic pleural effusion. Mayo Clin Proc 70:1161-1164, 1995.
28. Tefferi A, Silverstein MN, Plumhoff EA, et al: Suramin toxicity and efficacy in agnogenic myeloid metaplasia. J Natl Cancer Inst 85:1520-1522, 1993.
29. Ariel P, Nicodeme R, Adoue D, et al: Clinical evidence of 1,25-hydroxycholecalciferol action in myelofibrosis. Lancet 1:1013-1014, 1984 (letter to editor).
30. Creemers GJ, Lowenberg B, Hagenbeek A: Allogeneic bone marrow transplantation for primary myelofibrosis. Br J Haematol 82:772-773, 1992.
31. Dokal I, Jones L, Deenmamode M, et al: Allogeneic bone marrow transplantation for primary myelofibrosis. Br J Haematol 71:158-160, 1989.
32. Ifrah N, Gardembas-Pain M, Hunault M, et al: Allogeneic bone marrow transplantation for primary myelofibrosis. Br J Haematol 73:575-576, 1989 (letter to editor).